

## **Supplementary Materials**

### **Cilostazol vs Aspirin in Ischaemic Stroke with Cerebral Microbleeds vs Prior Intracerebral Haemorrhage**

Hong-Kyun Park, MD, MSc<sup>1</sup>; Ji Sung Lee, PhD<sup>2</sup>; Bum Joon Kim, MD, PhD<sup>3</sup>; Jong-Ho Park, MD, PhD<sup>4</sup>; Yong-Jae Kim, MD, PhD<sup>5</sup>; Sungwook Yu, MD, PhD<sup>6</sup>; Yang-Ha Hwang, MD, PhD<sup>7</sup>; Joung-Ho Rha, MD, PhD<sup>8</sup>; Sung Hyuk Heo, MD, PhD<sup>3</sup>; Seong Hwan Ahn, MD, PhD<sup>9</sup>; Woo-Keun Seo, MD, PhD<sup>10</sup>; Jong-Moo Park, MD, PhD<sup>11</sup>; Ju-Hun Lee, MD, PhD<sup>12</sup>; Jee-Hyun Kwon, MD, PhD<sup>13</sup>; Sung-Il Sohn, MD, PhD<sup>14</sup>; Jin-Man Jung, MD, PhD<sup>15</sup>; Sun U Kwon, MD, PhD<sup>16\*</sup>; Keun-Sik Hong, MD, PhD<sup>1\*</sup>, on behalf of the PICASSO investigators

<sup>1</sup>Department of Neurology, Inje University Ilsan Paik Hospital, Goyang, Korea

<sup>2</sup>Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

<sup>3</sup>Department of Neurology, Kyung Hee University Medical Center, Seoul, Korea

<sup>4</sup>Department of Neurology, Myungji Hospital, Hanyang University College of Medicine, Goyang, Korea

<sup>5</sup>Department of Neurology, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea

<sup>6</sup>Department of Neurology, Anam Hospital, Korea University, Seoul, Korea

<sup>7</sup>Department of Neurology, Kyungpook National University Hospital, Daegu, Korea

<sup>8</sup>Department of Neurology, Inha University Hospital, Incheon, Korea

<sup>9</sup>Department of Neurology, Chosun University School of Medicine and Hospital, Gwangju, Korea

<sup>10</sup>Department of Neurology, Samsung Medical Center, Sunkkyunkwan University, Seoul, Korea

<sup>11</sup>Department of Neurology, Nowon Eulji Medical Center, Eulji University, Seoul, Korea

<sup>12</sup>Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University, Seoul, Korea

<sup>13</sup>Department of Neurology, Ulsan University Hospital, Ulsan University, Ulsan, Korea

<sup>14</sup>Department of Neurology, Dongsan Medical Center, Keimyung University, Daegu, Korea

<sup>15</sup>Department of Neurology, Ansan Hospital, Korea University, Seoul, Korea

<sup>16</sup>Department of Neurology, Asan Medical Center, Ulsan University, Seoul, Korea

Supplementary Tables: 2

Supplementary Figures: 2

**Table I.** Comparison of mean blood pressures during the follow up period between the CMB and prior ICH subgroups, and cilostazol and aspirin arm in each group

**Table II.** Sensitivity analysis by recategorizing 17 patients with concurrent prior ICH and multiple CMBs into the CMBs subgroup

### Figure Legends

#### **Figure I. Kaplan-Meier curves for secondary endpoints in the cilostazol and aspirin arms for the CMBs and prior ICH subgroups**

(A) stroke (ischaemic or haemorrhagic), (B) ischaemic stroke, (C) myocardial infarction, (D) vascular death, (E) other vascular event, and (F) all-cause death

CMB, Cerebral microbleeds; ICH, Intracerebral haemorrhage

#### **Figure II. Kaplan-Meier curves for secondary endpoints according to the CMBs and prior ICH subgroups**

(A) stroke (ischaemic or haemorrhagic), (B) ischaemic stroke, (C) myocardial infarction, (D) vascular death, (E) other vascular event, and (F) all-cause death

CMB, Cerebral microbleeds; ICH, Intracerebral haemorrhage

**Supplementary Table I.** Comparison of mean blood pressures during the follow up period between the CMB and prior ICH subgroups, and cilostazol and aspirin arm in each group

	CMBs				Prior ICH				
	Overall (n=903)	Cilostazol (n=449)	Aspirin (n=454)	P†	Overall (n=903)	Cilostazol (n=449)	Aspirin (n=454)	P†	P‡
SBP	131.5 (11.6)	130.8 (11.5)	132.1 (11.6)	0.096	131.1 (11.5)	130.8 (11.8)	131.4 (11.2)	0.527	0.534
DBP	77.8 (8.2)	77.5 (8.2)	78.2 (8.3)	0.212	77.8 (7.5)	77.8 (7.6)	77.8 (7.4)	0.996	0.901

CMBs, Cerebral microbleeds; ICH, Intracerebral hemorrhage; SBP, Systolic blood pressure; DBP, Diastolic blood pressure

Data are n (%), mean (SD),

All p-value by Pearson's chi-square test or Fisher's exact test for categorical variables and Student's t-test or Wilcoxon rank sum test for continuous variables as appropriate

†P value corresponds to comparison of variables between the cilostazol and aspirin arms in each subgroup

‡P value corresponds to comparison between the CMBs and prior ICH subgroups for each characteristic


**Supplementary Table II.** Sensitivity analysis by recategorizing 17 patients with concurrent prior ICH and multiple CMBs into the CMBs subgroup

	Cilostazol, rate per 100 person- years (n*)	Aspirin, rate per 100 person- years (n*)	Hazard Ratio (95% CI)	P-value	P- value for interac- tion
Cerebral haemorrhage (ICH or subarachnoid haemorrhage)					0.0114
CMBs	0.12 (1)	1.47 (13)	0.08 (0.01-0.61)	0.0147	
Prior ICH	1.28 (8)	0.80 (5)	1.59 (0.52-4.86)	0.4162	
Composite of vascular event					0.2630
CMBs	3.76 (32)	5.56 (49)	0.67 (0.43-1.05)	0.0821	
Prior ICH	4.96 (31)	4.99 (31)	0.99 (0.60-1.62)	0.9571	
Stroke (ischaemic or haemorrhagic)					0.3206
CMBs	2.82 (24)	4.99 (44)	0.56 (0.34-0.92)	0.0232	
Prior ICH	3.84 (24)	4.67 (29)	0.82 (0.47-1.40)	0.4600	
Ischaemic stroke					0.8237
CMBs	2.70 (23)	3.52 (31)	0.76 (0.45-1.31)	0.3290	
Prior ICH	2.72 (17)	3.86 (24)	0.70 (0.37-1.30)	0.2533	
Myocardial infarction					0.8670
CMBs	0.59 (5)	0.11 (1)	5.19 (0.61-44.39)	0.1328	
Prior ICH	0.64 (4)	0.16 (1)	3.99 (0.45-35.72)	0.2157	
Other vascular event					0.4103
CMBs	0.71 (6)	1.13 (10)	0.62 (0.22-1.70)	0.3495	
Prior ICH	0.48 (3)	0.32 (2)	1.46 (0.24-8.76)	0.6768	
Vascular death					0.3124
CMBs	0.35 (3)	0.45 (4)	0.78 (0.17-3.49)	0.7454	

Prior ICH	0.80 (5)	0.32 (2)	2.45 (0.48-12.64)	0.2839	
All-cause death					0.7769
CMBs	1.64 (14)	1.92 (17)	0.86 (0.42-1.73)	0.6643	
Prior ICH	2.24 (14)	2.25 (14)	0.99 (0.47-2.08)	0.9820	

CMBs, Cerebral microbleeds; ICH, Intracerebral haemorrhage


\*Total number of events during the study period.



## Supplementary Figure I. Kaplan-Meier curves for secondary endpoints in the cilostazol and aspirin arms for the CMBs and prior ICH subgroups

(A) stroke (ischaemic or haemorrhagic), (B) ischaemic stroke, (C) myocardial infarction, (D) vascular death, (E) other vascular event, and (F) all-cause death

CMB, Cerebral microbleeds; ICH, Intracerebral haemorrhage



**Supplementary Figure II.** Kaplan-Meier curves for secondary endpoints according to the CMBs and prior ICH subgroups

(A) stroke (ischaemic or haemorrhagic), (B) ischaemic stroke, (C) myocardial infarction, (D) vascular death, (E) other vascular event, and (F) all-cause death

CMB, Cerebral microbleeds; ICH, Intracerebral haemorrhage